Q1 2024 13F Holders as of 31 Mar 2024
-
Type / Class
-
Equity / Common Stock, $0.0001 par value per share
-
Shares outstanding
-
30,284,111
-
Total 13F shares
-
31,373,529
-
Share change
-
+6,293,893
-
Total reported value
-
$2,076,887,534
-
Put/Call ratio
-
72%
-
Price per share
-
$66.20
-
Number of holders
-
144
-
Value change
-
+$418,851,985
-
Number of buys
-
92
-
Number of sells
-
47
Institutional Holders of Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) as of Q1 2024
As of 31 Mar 2024,
Keros Therapeutics, Inc. - Common Stock, $0.0001 par value per share (KROS) was held by
144 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
31,373,529 shares.
The largest 10 holders included
FMR LLC, BlackRock Inc., ALKEON CAPITAL MANAGEMENT LLC, STATE STREET CORP, VANGUARD GROUP INC, Darwin Global Management, Ltd., ORBIMED ADVISORS LLC, PRICE T ROWE ASSOCIATES INC /MD/, Point72 Asset Management, L.P., and TCG Crossover Management, LLC.
This page lists
143
institutional shareholders reporting positions in this security
for the Q1 2024 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.